As of Q3'25, CVS reported total revenues of approximately 59.4B USD in Pharmacy, 5.2B USD in Front Store, 33.7B USD in Premiums, 632M USD in Net investment income, and 3.8B USD in Other segments. The Pharmacy segment remains the dominant contributor, followed by Premiums, highlighting the company's continued reliance on these core areas. Over the period from Q4'22 to Q3'25, the chart shows that Pharmacy revenue has generally trended upward with some quarterly fluctuations, peaking at 59.7B USD in Q4'23 and maintaining strength thereafter. Premiums have shown steady growth, especially from Q1'24 onward, while Front Store revenue has remained relatively stable with minor declines. Net investment income and Other segments, though smaller in scale, have both experienced moderate increases, particularly since early 2024. Overall, CVS's revenue mix demonstrates a strong and growing foundation in Pharmacy and Premiums, with other segments providing incremental support.